Cubist announces European Medicines Agency acceptance of ceftolozane/tazobactam MAA
Cubist announced the EMA has accepted for review the Company’s Marketing Authorization Application for its investigational antibiotic ceftolozane/tazobactam. Cubist is seeking approval of ceftolozane/tazobactam for treatment of complicated urinary tract and intra-abdominal infections. August 22, 2014